Erratum: Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase (Cancer Res (2016) 76 (5743-5755) DOI: 10.1158/0008-5472.CAN-16-0268);Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase

Cancer Research

Volumn 76, Issue 19, 2016, Pages 5743-5755

  He, Xiaozhen ^a,b   Yan, Bin ^a,b   Liu, Shuang ^a   Jia, Jiantao ^a,b   Lai, Weiwei ^a,b   Xin, Xing ^a,b   Tang, Can E ^a   Luo, Dixian ^c   Tan, Tan ^c   Jiang, Yiqun ^a,b   Shi, Ying ^a,b   Liu, Yating ^a,b   Xiao, Desheng ^a   Chen, Ling ^a,b   Liu, Shao ^a   Mao, Chao ^a,b   Yin, Gang ^b   Cheng, Yan ^a   Fan, Jia ^d   Cao, Ya ^a,b   Muegge, Kathrin ^e   Tao, Yongguang ^a,b   more..

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

^d FUDAN UNIVERSITY   (China)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARATE HYDRATASE; HELICASE; I KAPPA B KINASE ALPHA; LYMPHOID SPECIFIC HELICASE; UNCLASSIFIED DRUG; 2 OXOGLUTARIC ACID; ALPHA-KETOGLUTARIC ACID; CITRIC ACID; DNA HELICASE; HELLS PROTEIN, HUMAN; PROTEIN ZO1; TJP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CHROMATIN ASSEMBLY AND DISASSEMBLY; CITRIC ACID CYCLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME REPRESSION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA INTERFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA; DISEASE COURSE; ENZYMOLOGY; HUMAN; METABOLISM; NASOPHARYNGEAL NEOPLASMS; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CITRIC ACID; CITRIC ACID CYCLE; DISEASE PROGRESSION; DNA HELICASES; EPITHELIAL-MESENCHYMAL TRANSITION; FUMARATE HYDRATASE; HUMANS; KETOGLUTARIC ACIDS; MICE; NASOPHARYNGEAL NEOPLASMS; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84989928165     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-22-0457     Document Type: Erratum

References (56)

1. Katada S, Imhof A, Sassone-Corsi P. Connecting threads: Epigenetics and metabolism. Cell 2012;148:24-8.
2. Kaelin WGJr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell 2013;153:56-69.
3. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012;16:9-17.
4. Gut P, Verdin E. The nexus of chromatin regulation and intermediary metabolism. Nature 2013;502:489-98.
5. Zemach A, Kim MY, Hsieh PH, Coleman-Derr D, Eshed-Williams L, Thao K, et al. The Arabidopsis nucleosome remodeler DDM1 allows DNA methyltransferases to access H1-containing heterochromatin. Cell 2013;153: 193-205.
6. Yu W, McIntosh C, Lister R, Zhu I, Han Y, Ren J, et al. Genome-wide DNA methylation patterns in LSH mutant reveals de-repression of repeat elements and redundant epigenetic silencing pathways. Genome Res 2014;24:1613-23.
7. Tao Y, Xi S, Shan J, Maunakea A, Che A, Briones V, et al. Lsh, chromatin remodeling family member, modulates genome-wide cytosine methylation patterns at nonrepeat sequences. Proc Natl Acad Sci U S A 2011;108:5626-31.
8. Myant K, Termanis A, Sundaram AY, Boe T, Li C, Merusi C, et al. LSH and G9a/GLP complex are required for developmentally programmed DNA methylation. Genome Res 2011;21:83-94.
9. Fan T, Yan Q, Huang J, Austin S, Cho E, Ferris D, et al. Lsh-deficient murine embryonal fibroblasts show reduced proliferation with signs of abnormal mitosis. Cancer Res 2003;63:4677-83.
10. Burrage J, Termanis A, Geissner A, Myant K, Gordon K, Stancheva I. The SNF2 family ATPase LSH promotes phosphorylation ofH2AX and efficient repair of DNA double-strand breaks in mammalian cells. J Cell Sci 2012;125(Pt 22):5524-34.
11. Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, et al. DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2011;8:164-76.
12. von Eyss B, Maaskola J, Memczak S, Mollmann K, Schuetz A, Loddenkemper C, et al. The SNF2-like helicase HELLS mediates E2F3- dependent transcription and cellular transformation. EMBO J 2012; 31:972-85.
13. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
14. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
15. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
16. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-110.
17. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96.
18. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013;19:1438-49.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
20. Desideri E, Vegliante R, Ciriolo MR. Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity. Cancer Lett 2015;356(2 Pt A):217-23.
21. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009;360:813-5.
22. Adam J, Yang M, Soga T, Pollard PJ. Rare insights into cancer biology. Oncogene 2014;33:2547-56.
23. Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: A cancer hallmarks analysis. Cell Host Microbe 2014;15:266-82.
24. Lieberman PM. Virology. Epstein-Barr virus turns 50. Science 2014;343: 1323-5.
25. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013;339:1567-70.
26. Chen T, Dent SY. Chromatin modifiers and remodellers: Regulators of cellular differentiation. Nat Rev Genet 2014;15:93-106.
27. Shi Y, Tao Y, Jiang Y, Xu Y, Yan B, Chen X, et al. Nuclear epidermal growth factor receptor interacts with transcriptional intermediary factor 2 to activate cyclin D1 gene expression triggered by the oncoprotein latent membrane protein 1. Carcinogenesis 2012;33:1468-78.
28. Jiang Y, Yan B, Lai W, Shi Y, Xiao D, Jia J, et al. Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8. Oncogene 2015;34:6079-91.
29. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
30. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004;5:423-8.
31. Raab-Traub N. Epstein-Barr virus transforming proteins: Biologic properties and contribution to oncogenesis. In:Damania B, Pipas JM, editors. DNA tumor viruses. New York, NY: Springer; 2009. p. 259-84.
32. Ren J, Briones V, Barbour S, Yu W, Han Y, Terashima M, et al. The ATP binding site of the chromatin remodeling homolog Lsh is required for nucleosome density and de novo DNA methylation at repeat sequences. Nucleic Acids Res 2015;43:1444-55.
33. Shinkai Y, Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev 2011;25:781-8.
34. Shanmugasundaram K, Nayak B, Shim EH, Livi CB, Block K, Sudarshan S. The oncometabolite fumarate promotes pseudohypoxia through noncanonical activation of NF-kappaB signaling. J Biol Chem 2014; 289:24691-9.
35. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003;423:659-63.
36. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 2003;423:655-9.
37. Huang WC, Ju TK, Hung MC, Chen CC. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell 2007;26:75-87.
38. Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 2009;19:438-51.
39. Yu W, Briones V, Lister R, McIntosh C, Han Y, Lee EY, et al. CG hypomethylation in Lsh-/- mouse embryonic fibroblasts is associated with de novo H3K4me1 formation and altered cellular plasticity. Proc Natl Acad Sci U S A 2014;111:5890-5.
40. Waseem A, Ali M, Odell EW, Fortune F, Teh MT. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol 2010;46:536-42.
41. Ryu B, Kim DS, Deluca AM, Alani RM. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2007;2:e594.
42. Tao Y, Liu S, Briones V, Geiman TM, Muegge K. Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS. Nucleic Acids Res 2011;39:9508-20.
43. Tao Y, Xi S, Briones V, Muegge K. Lsh mediated RNA polymerase II stalling at HoxC6 and HoxC8 involvesDNAmethylation. PLoSOne 2010;5:e9163.
44. Adam J, Yang M, Bauerschmidt C, Kitagawa M, O'Flaherty L, Maheswaran P, et al. A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia. Cell Rep 2013;3:1440-8.
45. Ternette N, Yang M, Laroyia M, Kitagawa M, O'Flaherty L, Wolhulter K, et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep 2013;3:689-700.
46. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-10.
47. Zheng L, Cardaci S, Jerby L, MacKenzie ED, Sciacovelli M, Johnson TI, et al. Fumarate induces redox-dependent senescence by modifying glutathione metabolism. Nat Commun 2015;6:6001.
48. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flightmass spectrometry. Cancer Res 2009;69:4918-25.
49. Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 2015;162:1217-28.
50. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2- hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17-30.
51. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479-83.
52. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 2015;518:413-6.
53. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014;54: 716-27.
54. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527: 525-30.
55. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527: 472-6.
56. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumormicroenvironment is a driver of cancer progression. Cell 2015;162:1229-41.